Toggle Main Menu Toggle Search

Open Access padlockePrints

Phosphodiesterase III inhibitor promotes drainage of cerebrovascular beta-amyloid

Lookup NU author(s): Dr Yoshiki Hase, Professor Raj Kalaria, Dr Masafumi Ihara

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

Objective: Brain amyloidosis is a key feature of Alzheimer's disease (AD). It also incorporates cerebrovascular amyloid beta (A beta) in the form of cerebral amyloid angiopathy (CAA) involving neurovascular dysfunction. We have recently shown by retrospective analysis that patients with mild cognitive impairment receiving a vasoactive drug cilostazol, a selective inhibitor of phosphodiesterase (PDE) III, exhibit significantly reduced cognitive decline. Here, we tested whether cilostazol protects against the disruption of the neurovascular unit and facilitates the arterial pulsation-driven perivascular drainage of A beta in AD/CAA. Methods: We explored the expression of PDE III in postmortem human brain tissue followed by a series of experiments examining the effects of cilostazol on A beta metabolism in transgenic mice (Tg-SwDI mice) as a model of cerebrovascular beta-amyloidosis, as well as cultured neurons. Results: We established that PDE III is abnormally upregulated in cerebral blood vessels of AD and CAA subjects and closely correlates with vascular amyloid burden. Furthermore, we demonstrated that cilostazol treatment maintained cerebral hyperemic and vasodilative responses to hypercapnia and acetylcholine, suppressed degeneration of pericytes and vascular smooth muscle cells, promoted perivascular drainage of soluble fluorescent A beta(1-40), and rescued cognitive deficits in Tg-SwDI mice. Although cilostazol decreased endogenous A beta production in cultured neurons, C-terminal fragment of amyloid precursor protein expression was not altered in cilostazol-treated Tg-SwDI mice. Interpretation: The predominant action of cilostazol on A beta metabolism is likely to facilitate A beta clearance due to the sustained cerebrovascular function in vivo. Our findings mechanistically demonstrate that cilostazol is a promising therapeutic approach for AD and CAA.


Publication metadata

Author(s): Maki T, Okamoto Y, Carare RO, Hase Y, Hattori Y, Hawkes CA, Saito S, Yamamoto Y, Terasaki Y, Ishibashi-Ueda H, Taguchi A, Takahashi R, Miyakawa T, Kalaria RN, Lo EH, Arai K, Ihara M

Publication type: Article

Publication status: Published

Journal: Annals of Clinical and Translational Neurology

Year: 2014

Volume: 1

Issue: 8

Pages: 519-533

Print publication date: 01/08/2014

Online publication date: 08/07/2014

Acceptance date: 02/06/2014

Date deposited: 26/07/2018

ISSN (electronic): 2328-9503

Publisher: Wiley-Blackwell Publishing, Inc.

URL: https://doi.org/10.1002/acn3.79

DOI: 10.1002/acn3.79


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share